News and Updates
January 14, 2026
Rejuve Files Provisional Patent Application for Cellular Rejuvenation Technology
Rejuve Therapeutics filed U.S. Provisional Patent Application No. 63/960,217, titled “Methods for Rejuvenating Mammalian Cells.”
The application describes controlled approaches designed to rejuvenate aged or senescent mammalian cells while preserving their original cellular identity, including methods intended to limit dedifferentiation during cellular reprogramming. It also covers screening approaches for identifying and evaluating potential cellular rejuvenation interventions.
This filing established an initial intellectual-property foundation for Rejuve’s development of safer and more precisely controlled cellular rejuvenation technologies.
March 5, 2026
Derya Unutmaz, MD, Joins Rejuve’s Scientific Advisory Board
Rejuve Therapeutics welcomed Derya Unutmaz, MD, to its Scientific Advisory Board.
Dr. Unutmaz is a professor at The Jackson Laboratory for Genomic Medicine and an internationally recognized immunologist whose research examines human T-cell differentiation, activation and regulation in immune responses, chronic diseases and aging.
His expertise in human immunology, cellular differentiation, aging biology and data-driven biomedical research will support Rejuve’s investigation of the molecular mechanisms of cellular aging and its development of strategies to restore youthful cellular function while preserving cell identity.
June 22, 2026
Rejuve Establishes Sponsored Research Collaboration for Computational Analysis of Cellular Aging
Rejuve Therapeutics entered into a sponsored research agreement with a leading U.S. research university to support advanced computational analysis of Rejuve’s Longitudinal Aging and Rejuvenation Gene Expression Atlas.
Rejuve is developing this proprietary single-cell dataset using primary human arterial endothelial cells across five interconnected biological trajectories:
- Replicative aging and cellular senescence
- Controlled cellular rejuvenation under defined experimental conditions
- Reprogramming-related cellular transitions
- Differentiation-related cellular transitions
- Dedifferentiation-related cellular transitins
The collaboration will apply advanced computational and machine-learning methods to characterize major and intermediate cellular states, reconstruct molecular trajectories and identify transcriptional programs associated with aging, rejuvenation and preservation of endothelial identity.
The research will also compare shared and trajectory-specific molecular features and prioritize candidate regulatory genes, pathways and gene combinations for downstream experimental validation by Rejuve.
Certain details, including the identity of the institution and principal investigator, are not included in this announcement in accordance with applicable contractual publicity obligations.
June 28, 2026
Rejuve Files U.S. Nonprovisional Patent Application
Rejuve Therapeutics filed U.S. Nonprovisional Patent Application No. 19/722,877, titled “Methods for Rejuvenating Mammalian Cells,” advancing the intellectual-property protection initiated through its January 2026 provisional filing.
The application covers controlled approaches intended to rejuvenate aged or senescent mammalian cells while preserving their original cellular identity. It also includes screening methods for identifying and evaluating potential cellular rejuvenation interventions.
The filing represents an important step in Rejuve’s strategy to translate its cellular-rejuvenation discoveries into a protected therapeutic-development platform.
July 18, 2026
Rejuve Expands Its Computational Discovery Program Through Agreement with Strata Biolab Inc
Rejuve Therapeutics entered into an AI and data-analysis services agreement with Strata Biolab, together with an initial statement of work focused on Rejuve’s proprietary human arterial endothelial cell aging and rejuvenation single-cell RNA-sequencing dataset.
Under the agreement, Strata will apply agentic AI-enabled computational biology, machine learning, statistical analysis and related analytical workflows to identify and prioritize candidate regulatory genes, gene programs, pathways and network features associated with endothelial aging, cellular senescence, rejuvenation, differentiation and cellular reprogramming.
The Strata engagement complements—and does not replace—Rejuve’s existing sponsored research collaboration announced on June 22, 2026. The two programs have separately defined scopes and provide complementary analytical capabilities and perspectives.
Together, these efforts are intended to strengthen biological interpretation of Rejuve’s longitudinal dataset, accelerate hypothesis generation and prioritize promising genes, pathways and potential rejuvenation interventions for downstream experimental validation and platform development.